image credit- shutterstock
South Korea-based startup Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has signed a Memorandum of Understanding (MoU) with the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET).
The agreement aims to support healthcare professionals participating in ALZ-NET and enhance the quality of care for patients with Alzheimer's disease. Under the partnership, the two parties will work to raise awareness of the importance of monitoring Amyloid-Related Imaging Abnormalities (ARIA), while also providing discounted access to Neurophet's key solutions across medical institutions participating in ALZ-NET and expanding their clinical utilization.
The collaboration will involve Neurophet's flagship solutions, including Neurophet AQUA, a brain neurodegeneration imaging analysis software;Neurophet SCALE PET, a quantitative Positron Emission Tomography (PET) imaging analysis software; Neurophet AQUA AD Plus, an integrated brain imaging analysis solution designed to support treatment decision-making for Alzheimer's disease therapies.
Neurophet AQUA, Neurophet SCALE PET, and Neurophet AQUA AD Plus have each received 510(k) clearance from the US Food and Drug Administration (FDA). A number of Alzheimer's disease treatment medical centers and neuroimaging facilities participating in ALZ-NET are expected to leverage Neurophet's key solutions going forward.
Sponsored by the Alzheimer's Association and managed and operated by the American College of Radiology (ACR), ALZ-NET is an Alzheimer's treatment and diagnostics network that collects and analyzes clinical and imaging data from patients receiving novel FDA-approved Alzheimer's therapies through voluntarily participating medical institutions. Through these efforts, ALZ-NET supports the advancement of clinical evidence and the standardisation of care in the field of Alzheimer's treatment and diagnostics.
